Conditioning vaccination site with irradiated MIP-3alpha-transfected tumor cells enhances efficacy of dendritic cell-based cancer vaccine
/in Dendritic Cells, International Publications /von 2009-05-01 / J. Immunother. 2009 May;32(4):363-9Tumor specific cytotoxicity and telomerase down-regulation in prostate cancer by autologous dendritic cells loaded with whole tumor cell antigens
/in Dendritic Cells, International Publications, Prostate Cancer /von 2009-04-11 / Urol. Oncol. 2010 May-Jun;28(3):290-5Vaccination strategies in patients with renal cell carcinoma
/in Dendritic Cells, Hypernephroma, International Publications /von 2009-04-10 / Cancer Immunol. Immunother. 2009 Jul;58(7):1169-74A combination therapy of gemcitabine with immunotherapy for patients with inoperable locally advanced pancreatic cancer
/in Dendritic Cells, International Publications, Pancreatic Cancer /von 2009-04-01 / Pancreas 2009 Apr;38(3):e69-74DCVax-Brain and DC vaccines in the treatment of GBM
/in Dendritic Cells, Glioblastoma, International Publications /von 2009-04-01 / Expert Opin Investig Drugs 2009 Apr;18(4):509-19Limited amounts of dendritic cells migrate into the T-cell area of lymph nodes but have high immune activating potential in melanoma patients
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2009-03-24 / Clin. Cancer Res. 2009 Apr;15(7):2531-40Costimulatory ligand CD70 allows induction of CD8+ T-cell immunity by immature dendritic cells in a vaccination setting
/in Dendritic Cells, International Publications /von 2009-03-11 / Blood 2009 May;113(21):5167-75Ampligen: a potential toll-like 3 receptor adjuvant for immunotherapy of cancer
/in Dendritic Cells, International Publications /von 2009-02-05 / Vaccine 2009 May;27(25-26):3401-4Antitumoral immune response by recruitment and expansion of dendritic cells in tumors infected with telomerase-dependent oncolytic viruses
/in Dendritic Cells, International Publications, Newcastle Disease Virus /von 2009-02-03 / Cancer Res. 2009 Feb;69(4):1448-58
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies
- Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum
- Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution